GLP-1 Pill vs Injection 2026: Rybelsus, Wegovy, Orforglipron Compared
Why most weight-loss GLP-1s are injectable, where oral GLP-1 stands in 2026, and what the FDA-approval pipeline looks like for orforglipron and other oral candidates.
The most common GLP-1 question in 2026 isn't "does it work?" — it's "do I have to inject myself?" Among FDA-approved weight-loss GLP-1 medications, the answer is yes: weekly subcutaneous injection. Oral GLP-1 exists in limited form (Rybelsus, FDA-approved for type 2 diabetes only), and Eli Lilly's investigational orforglipron tablet is in late-stage trials — but as of May 2026, every FDA-approved weight-loss GLP-1 is injectable.
Side-by-side: oral vs injection in 2026
| Rybelsus (oral semaglutide) | Wegovy (injectable semaglutide) | Orforglipron (oral, investigational) | |
|---|---|---|---|
| FDA approved for weight loss | ❌ | ✅ | Not yet (pending) |
| FDA approved for diabetes | ✅ | ❌ (sister: Ozempic) | Not yet |
| Dose frequency | Daily, fasting AM | Weekly | Daily (expected) |
| Bioavailability | <1% | ~90% | ~10% (Phase 3 data) |
| Mean weight loss | ~4% (PIONEER trials) | 15-17% (STEP 1) | ~14-15% (Phase 3) |
| Brand-name list price (US, mo) | ~$1,000 | ~$1,349 | TBD |
Why weight-loss GLP-1s are mostly injectable
GLP-1 is a 30-amino-acid peptide hormone. Like insulin and most other peptide drugs, it's vulnerable to two big GI obstacles: stomach acid hydrolyzes the peptide bonds, and digestive enzymes (pepsin, trypsin, chymotrypsin) further degrade it. Without protection, oral GLP-1 would have effectively zero bioavailability.
Rybelsus solves this with SNAC — sodium N-(8-[2-hydroxybenzoyl]amino) caprylate — an absorption enhancer that temporarily increases the intestinal-wall permeability, letting a small fraction of intact semaglutide through. Even with SNAC, oral semaglutide's bioavailability is <1%, which is why Rybelsus tablets contain 3-14 mg of semaglutide vs the 2.4 mg/week subcutaneous Wegovy dose: most of the oral dose is destroyed before it reaches the bloodstream.
Orforglipron solves it differently — it's a small-molecule GLP-1 receptor agonist (not a peptide), so it survives the GI tract on its own. That gives it ~10% bioavailability (Phase 3 data), enough for meaningful clinical effect at oral doses similar to injectables.
FDA-approved injectable GLP-1s for weight loss (2026)
| Brand | Active ingredient | Dose schedule | Mean weight loss (trial) |
|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | Once weekly | 15-17% (STEP 1, NEJM 2021) |
| Zepbound | Tirzepatide up to 15 mg | Once weekly | 20-22.5% (SURMOUNT-1, NEJM 2022) |
| Saxenda | Liraglutide 3.0 mg | Once daily | ~8% (SCALE, JAMA 2015) |
| Compounded semaglutide | Semaglutide (same molecule as Wegovy) | Once weekly | Same expected as Wegovy 15-17% |
Compounded GLP-1: still injectable
Trimi's compounded semaglutide ($99/mo annual) and compounded tirzepatide ($125/mo annual) are both subcutaneous injection vials, drawn into a small syringe (30-32 gauge needle) once weekly. The active ingredients are identical to the FDA-approved Wegovy/Ozempic/Zepbound/Mounjaro brand products; the pharmacy compounds them per individual patient prescription under FDCA Section 503A. We don't offer compounded oral GLP-1 because the bioavailability and dose-equivalence evidence base is too limited to match the predictable pharmacokinetics of injection.
Orforglipron / Foundayo: the next oral option
Eli Lilly's orforglipron is the most-watched oral GLP-1 candidate in 2026. Phase 3 ACHIEVE-1 (type 2 diabetes) and ATTAIN-1 (chronic weight management) trials reported ~14-15% mean body-weight reduction at the highest dose — within striking distance of injectable semaglutide and approaching injectable tirzepatide territory. Foundayo is the brand name in some markets.
Why this matters: orforglipron is a small-molecule pill (not a peptide), so it doesn't need SNAC-style absorption enhancement and isn't subject to the <1% bioavailability limitation that holds Rybelsus back. It's also expected to be much cheaper to manufacture at scale than injectable peptide GLP-1s.
Timeline as of May 2026: FDA approval submission expected H1 2026, possible launch H2 2026 or early 2027. Pricing not announced. Lilly's pricing for Zepbound suggests $700-$1,200/month list — competitive with brand-name injectables.
Available now: weekly injection GLP-1
Trimi compounded semaglutide $99/mo or tirzepatide $125/mo (annual plan). Same active ingredients as Wegovy/Ozempic and Zepbound/Mounjaro.
Start your visitFAQs: GLP-1 pill vs injection
Are there any FDA-approved GLP-1 pills for weight loss?
As of May 2026, no GLP-1 pill is FDA-approved for chronic weight management. Rybelsus is oral semaglutide approved only for type 2 diabetes (not weight loss). Eli Lilly's oral orforglipron (an oral GLP-1 receptor agonist) is in late-stage clinical trials but not yet FDA-approved for any indication. For FDA-approved weight-loss GLP-1s, all current options are injectable: Wegovy (semaglutide 2.4 mg weekly), Zepbound (tirzepatide weekly), Saxenda (liraglutide daily).
Is Rybelsus the same as Wegovy?
Both are semaglutide, but they're different formulations and indications. Rybelsus is oral semaglutide (3 mg/7 mg/14 mg daily tablets) FDA-approved for type 2 diabetes only. Wegovy is subcutaneous injection semaglutide (up to 2.4 mg weekly) FDA-approved for chronic weight management. The active ingredient is the same molecule; the route of administration and approved dosing for weight loss differ. Rybelsus's oral bioavailability requires fasting and a special tablet coating (SNAC absorption enhancer); typical absorption is <1% of the dose.
Why are most weight-loss GLP-1s injectable?
GLP-1 is a peptide hormone that gets destroyed by stomach acid and digestive enzymes. To survive oral administration, the molecule needs special protection — Rybelsus uses SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate) as an absorption enhancer, which delivers <1% bioavailability and requires fasting. Subcutaneous injection bypasses the GI tract entirely, achieving consistent 90%+ bioavailability and predictable pharmacokinetics. For high-dose weight-loss therapy (2.4 mg semaglutide weekly), the injection route is more practical.
Is injection painful?
Subcutaneous GLP-1 injection uses a very thin needle (typically 30-32 gauge, 4-5 mm length) inserted into the fatty tissue just under the skin of the abdomen, thigh, or upper arm. Most patients describe it as a brief pinch or no sensation at all. Pen autoinjectors (Wegovy, Ozempic, Mounjaro, Zepbound) hide the needle so you only see a button press. Compounded GLP-1 vials (Trimi, etc.) require self-drawing into a small syringe but use the same thin-needle approach.
How often do injections happen vs pills?
FDA-approved injectable GLP-1s (Wegovy, Ozempic, Mounjaro, Zepbound) and most compounded GLP-1 (Trimi, Mochi, etc.) are once-weekly subcutaneous injections. Rybelsus oral semaglutide is once-daily (must be taken in the morning, on an empty stomach, with no more than 4 oz of water, then waiting 30+ minutes before any food). Daily oral dosing has worse adherence over time than weekly injection for most patients.
What about orforglipron, the new Eli Lilly pill?
Orforglipron is a small-molecule GLP-1 receptor agonist Eli Lilly is developing as an oral once-daily tablet for weight loss and type 2 diabetes. Phase 3 trials have reported ~14-15% mean body-weight reduction at the highest dose. As of May 2026, orforglipron is NOT FDA-approved. Lilly anticipates submitting for FDA approval and expects a launch decision in 2025-2026 (Foundayo brand-name in some markets). When approved, orforglipron would be the first FDA-approved oral GLP-1 for weight loss — but pricing is expected to be similar to brand-name injectables ($1,000+/month) given Lilly's existing pricing for Zepbound.
Can compounded GLP-1 be oral?
Compounded oral semaglutide exists from some pharmacies (sublingual or buccal-troche formulations), but evidence for bioequivalence with injectable semaglutide is limited. Most 503A pharmacies, including Trimi's primary partners VialsRx and GreenwichRx, dispense compounded GLP-1 as subcutaneous injection vials because pharmacokinetics are predictable and dosing matches the published clinical-trial regimens. Trimi does not offer compounded oral GLP-1.
Which is more effective for weight loss — pill or injection?
Injection. Weekly injectable semaglutide 2.4 mg (Wegovy) produces 15-17% mean body-weight reduction (STEP 1, NEJM 2021); tirzepatide 15 mg weekly (Zepbound) produces 20-22.5% (SURMOUNT-1, NEJM 2022). Oral Rybelsus 14 mg daily produces ~4% body-weight reduction (PIONEER trials, NEJM 2019-2020) — far less than injectable semaglutide because the oral bioavailability is <1% and the FDA-approved oral dose maxes out at 14 mg/day. Investigational orforglipron tablets (Eli Lilly) target ~14-15% but aren't yet approved.
Related reading
Full head-to-head comparison.
What we know about Lilly's oral GLP-1 pipeline.
Same molecule, different price.
Full pricing landscape.
Disclaimer: This article describes FDA-approved and investigational GLP-1 medications and is informational only — not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved as finished drugs; the active ingredients are FDA-approved as the basis for commercial brand products. Trimi does not currently offer oral GLP-1 medications. Orforglipron / Foundayo references reflect Eli Lilly's public statements and Phase 3 trial reports through May 2026; FDA approval status may change. Always consult a licensed clinician about whether any specific GLP-1 medication is appropriate for your situation. **The FDA does not review or approve any compounded medications for safety or effectiveness.